In a 72-week trial in adults with obesity without diabetes, the mean percentage change in weight was -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) vs -3.1% with placebo
Human evidence - Phase 2 NEJM (Jastreboff et al., 2023) 338 adults with obesity but no diabetes
Book your consultation and claim your limited-time offer now
Insurance coverage will vary by person and by insurance policy, and recently, more insurance plans have opted not to cover the cost of GLP-1 agonists, particularly those that are being prescribed for off-label use, Ngo-Hamilton says
Weight loss in month one typically ranges from 0-8 pounds depending on starting dose, caloric deficit, and individual metabolismthis variation is completely normal
To put that percentage into perspective against currently approved medications: Semaglutide (Wegovy): Produced approximately 14.9% average body weight reduction in its landmark STEP 1 trial over 68 weeks